Skip to main content
Minoxidil comes in two very different forms, and the difference matters. The liquid or foam applied to the scalp is a properly authorised medicine for male pattern hair loss in EU countries, sold both on prescription and over the counter. Minoxidil also exists as a tablet, but in the EU those tablets are only licensed as a blood-pressure medicine — taking low-dose minoxidil tablets for hair is off-label, meaning a doctor prescribes it outside its licensed use.
Active ingredient: minoxidil. Dosages: 5% topical solution or foam, or 2.5–5 mg oral (off-label for hair).

​
How it works

Applied to the scalp, minoxidil opens ATP-sensitive potassium channels, widens small blood vessels and appears to keep hair follicles in their growing phase for longer — although exactly how it acts on hair is still not fully understood.
A properly authorised EU medicine for male pattern hair loss, applied twice daily to a dry scalp — 1 mL, not rinsed for at least 4 hours. This is the form the trial evidence below is based on.

​
EU authorisation

Minoxidil has been authorised for use in the EU since 1 May 1988 (AEMPS CIMA, Regaxidil 20 mg/ml solución cutánea, Spain registration 57597, indicated for moderate androgenetic alopecia).

​
What the studies reported

The core hair-loss trial (Olsen et al., J Am Acad Dermatol 2002;47(3):377-385, PMID 12196747) ran for 48 weeks in men aged 18–49 with vertex-pattern loss, so it does not establish results beyond one year or in other patterns of hair loss.

​
What has been reported

Application-site reactions can occasionally be more severe and include peeling, blistering, bleeding or ulceration.
In a 24-week randomised trial of oral minoxidil 5 mg vs topical minoxidil 5% (n=45 per arm), hypertrichosis occurred in 22/45 (49%) on the oral drug vs 11/45 (25%) on topical (P=.02), and headache in 6/45 (14%) vs 1/45 (2%) (P=.046). Scalp eczema was more frequent with topical: 7/45 (16%) vs 1/45 (2%). (Penha MA, Miot HA, Kasprzak M, Muller Ramos P. JAMA Dermatol. 2024;160(6):600-605, PMID 38598226.)
In a retrospective multicentre study of 1,404 patients treated for at least 3 months, the most frequent adverse effect was hypertrichosis (15.1%, causing withdrawal in 0.5%). Systemic effects: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital oedema 0.3%, insomnia 0.2% — leading to discontinuation in 1.2% of patients. (Vaño-Gálvan S, Pirmez R, Hermosa-Gelbard A, et al. J Am Acad Dermatol. 2021;84(6):1644-1651, PMID 33639244.)
EU-authorised minoxidil tablets are indicated only for severe resistant high blood pressure, and their product information states they must never be used alone or as initial therapy — always alongside a beta-blocker and a diuretic. None of that licensed dosing framework applies to the low doses used off-label for hair loss.

​
How it pairs with other treatments

Minoxidil is frequently combined with a 5-alpha-reductase inhibitor: minoxidil stimulates the follicle while finasteride or dutasteride blocks the hormonal cause. The doctor decides the form and combination based on history and pattern of loss.

​
How Hi-Doctor handles it

Weeks 1–8 — build the daily routine. A doctor reviews every hair-growth option and recommends what fits the case history and goals — topical or oral, depending on presentation. The consultation fee is separate from the medicine, which is paid at a pharmacy; see pricing.

​
Sources

  • AEMPS CIMA — Regaxidil 20 mg/ml solución cutánea, ficha técnica (Spain, registration 57597, authorised 1 May 1988)
  • AEMPS CIMA — Regaine 50 mg/g espuma cutánea, ficha técnica (Spain, registration 76483)
  • AEMPS CIMA — Loniten 10 mg comprimidos, ficha técnica (Spain, registration 55636; oral minoxidil, severe hypertension only)
  • AEMPS CIMA — Minogal 2,5/5/10 mg comprimidos EFG, ficha técnica (Spain, registration 91045-91047, authorised 2026; oral minoxidil, severe resistant hypertension only)
  • Olsen et al., J Am Acad Dermatol 2002;47(3):377-385 (PMID 12196747)
  • Penha MA, Miot HA, Kasprzak M, Muller Ramos P. JAMA Dermatol. 2024;160(6):600-605 (PMID 38598226)
  • Vaño-Gálvan S, Pirmez R, Hermosa-Gelbard A, et al. J Am Acad Dermatol. 2021;84(6):1644-1651 (PMID 33639244)
  • Rodrigues Dias F, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B. Front Pharmacol. 2026;16:1718208

​
Common questions

First changes are usually seen at months 2–4 of consistent twice-daily use. The core trial ran for 48 weeks and does not establish results beyond one year. Results vary by person and pattern of hair loss.
The EU-authorised regimen is 1 mL applied twice daily to a dry scalp, not rinsed for at least 4 hours. Using it less often may reduce its effect. Discuss any change with your doctor.
Temporary increased shedding is listed in the EU product information at a frequency that is not known. This can happen in the first weeks as the hair cycle adjusts and usually resolves with continued use.
Low-dose oral minoxidil is prescribed off-label under medical supervision. In a large observational study of 1,404 patients, the most frequent side effect was unwanted hair growth (hypertrichosis) in 15.1%, and systemic effects leading to discontinuation occurred in 1.2%. Your doctor monitors for cardiovascular effects.
Yes. Minoxidil and finasteride work by different mechanisms — minoxidil stimulates the follicle while finasteride blocks the hormonal cause. The combination is frequently used. A doctor decides the form and combination based on your history.
Yes for the topical form. Minoxidil has been authorised for use in the EU since 1 May 1988 (AEMPS CIMA, Regaxidil 20 mg/ml solution cutánea, Spain registration 57597, indicated for moderate androgenetic alopecia). The oral tablet is authorised only for severe resistant high blood pressure.

​
Start a consultation

Hair-growth consultation

Answer the hair-growth questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.